In afternoon trade the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) is down a disappointing 0.3% to 5,654 points due partly to heavy declines in the information technology and telecommunications sectors.
Four shares which haven't let that hold them back are listed below. Here's why they have surged higher today:
The a2 Milk Company Ltd (Australia) (ASX: A2M) share price has continued its strong run and is up a further 2% to $5.98. Whilst I am a big fan of the company, I do think that its shares are looking a touch expensive at this point. In light of this, I would class the dairy company as a hold.
The Cynata Therapeutics Ltd (ASX: CYP) share price has climbed 5% to 69 cents after the stem cell and regenerative medicine company announced that its proprietary Cymerus mesenchymal stem cell technology has been granted a patent by the U.S. Patent and Trademark Office. The patent covers certain proprietary methods relating to the platform's ability to efficiently manufacture mesenchymal stem cells at scale.
The GetSwift Ltd (ASX: GSW) share price has surged 8% higher to $2.48 despite there being no news out of the logistics platform provider. But as I said earlier today, despite the 700%+ rise in its shares this year, I still believe its shares are great value considering the recent deals that it has signed.
The Neurotech International Ltd (ASX: NTI) share price has rocketed 60% to 26.5 cents after the neuroscience-focused medical solutions company announced preliminary findings from a clinical trial that included its Mente Autism device. According to the release, the changes observed in autistic children after a 12-week clinical trial are outstanding. The Mente Autism device is designed to help relax the minds of children on the spectrum, helping them focus better and engage positively with their environment.
